Clinical trial

A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)

NCT05121948

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention HC-7366 Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE1

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2022-02-23

PhasePHASE1

Conditions

Squamous Cell Carcinoma of Head and Neckverified · MONDO: head and neck squamous cell carcinoma

Colo-rectal Cancerunresolved

Non Small Cell Lung Cancercandidate · MONDO: non-small cell lung carcinoma

Transitional Cell Carcinoma of the Bladderunresolved

Other Solid Tumorsunresolved

Clear Cell Renal Cell Carcinomaverified · MONDO: clear cell renal carcinoma

Interventions

HC-7366DRUG

Sponsors & collaborators

HiberCell, Inc.lead sponsor

Covancecollaborator

Mapped research locations

NashvilleTennessee, United States2 HoustonTexas, United States1 St LouisMissouri, United States1 SeattleWashington, United States1 AuroraColorado, United States1 La JollaCalifornia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05121948 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.